TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: CYCPK    
Cyclosporine, Peak, Blood

Useful For Suggests clinical disorders or settings where the test may be helpful

Monitoring whole blood cyclosporine concentration during therapy, particularly in individuals coadministered CYP3A4 substrates, inhibitors, or inducers

 

Adjusting dose to optimize immunosuppression while minimizing toxicity

 

Evaluating patient compliance

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Cyclosporine is a lipophilic polypeptide used to prevent rejection after solid organ transplantation; it suppresses T-cell activation by inhibiting calcineurin to decrease interleukin-2 (IL-2) production. There is substantial interpatient variability in absorption, half-life, and other pharmacokinetic parameters. Cyclosporine is extensively metabolized by CYP3A4 to at least 30 less-active metabolites, many of which are detected by immunoassays. Cyclosporine is known for many drug interactions, including increased neuro- and nephrotoxicity when coadministered with antibiotics, antifungals, or other immunosuppressants. Cyclosporine has a narrow therapeutic range with frequent adverse effects making therapeutic drug monitoring essential. With 80% of cyclosporine sequestered in erythrocytes, whole blood is the preferred specimen for analysis.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

No definitive therapeutic or toxic ranges have been established.

 

Optimal blood drug levels are influenced by type of transplant, patient response, time posttransplant, coadministration of other drugs, and drug formulation.

 

The following 2-hour postdose cyclosporine ranges are only suggested guidelines:

Renal transplant: 800-1700 ng/mL

Liver transplant: 600-1000 ng/mL

 

Target steady-state peak concentrations vary depending on the type of transplant, concomitant immunosuppression, clinical/institutional protocols, and time posttransplant. Results should be interpreted in conjunction with this clinical information and any physical signs/symptoms of rejection/toxicity.

Interpretation Provides information to assist in interpretation of the test results

No definitive therapeutic or toxic ranges have been established for postdose peak monitoring. Preferred therapeutic ranges may vary by transplant type, protocol, and comedications. The 2-hour postdose cyclosporine ranges listed for this test are only suggested guidelines.

 

This assay is specific for cyclosporine; it does not cross-react with cyclosporine metabolites, sirolimus, sirolimus metabolites, tacrolimus, or tacrolimus metabolites. Results by liquid chromatography with detection by tandem mass spectrometry are approximately 30% less than by immunoassay.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

No definitive therapeutic or toxic ranges have been established for postdose peak monitoring. Preferred therapeutic ranges may vary by transplant type, protocol, and comedications.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Moyer TP, Post GR, Sterioff S, et al: Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood. Mayo Clin Proc 1988 March;63(3):241-247

2. Kahan BD, Keown P, Levy GA, et al: Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002 March; 24(3):330-350

3. Dunn CJ, Wagstaff AJ, Perry CM, et al: Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy, and tolerability of a microemulsion-based formulation (Neoral) 1 in organ transplantation. Drugs 2001;61(13):1957-2016